Why is Diligent Due Diligence Important?
Alex Bone, Patent Attorney, Partner, AA Thornton.
Background
Biopharma merger and acquisition activity was lower in 2021 than in recent years, but the top 10 deals still reached a combined value of over $50 billion. The main...
Drug delivery
Dr Jason Bellia, Senior Patent Examiner at the
UK Intellectual Property Office (IPO)
I will look at just two of a vast number of routes - one to deliver nucleic acids across cell membranes and another looking...
Patent Protection of Medical Devices – Time for a Rethink?
Christopher Burnett, Patent Attorney, AA Thornton
The duration of patent protection for medical devices is up to twenty years, as for any other type of device. Pharmaceuticals, on the other hand, may be entitled to an...
The Nagoya Protocol and the UK – Are you Compliant?
The Nagoya Protocol has been in force in the UK since October 2015 and obliges users of genetic resources and traditional knowledge associated with genetic resources to comply with due diligence requirements before its...
UK Supreme Court inflicts more patent pain on Warner-Lambert
Eilidh Pugh, Pharmaceutical Patent Attorney, AdamsonJones.
The UK Supreme Court has handed down its much-anticipated decision in WarnerLambert Company LLC v Generics (UK) Ltd t/a Mylan and Actavis. The case is important because it is the...
Compulsory licensing of pharmaceuticals: A solution to high drug prices?
The UK continues to grapple with its departure – or not – from the European Union, and whilst the outcome remains unclear, one thing now seems certain: before long there will be a general...
Creating a Corona Vaccine
Varuni Paranavitane, IP Solicitor, AA Thornton.
As the world faces unprecedented challenges caused by the SARS-Cov-2 virus, we look at the science behind vaccine technology being investigated and how intellectual property rights may play a part...
Considering a pharma and bioscience patent? The UK Intellectual Property Office maps out the...
Lawrence Cullen & Laura Starrs, Patent Examining Group Heads, IPO
Managing a patent portfolio requires, among many skills, the ability to anticipate the future. This is especially true in the fields of bioscience and pharma where,...
Protecting Digital Medtech Innovation
For many years the medical technology (medtech) sector has been at the forefront of innovation and the Covid-19 pandemic has not slowed it down, with new technology quickly being developed to test for, prevent...
Biosimilars and Patents
Leonita Paulraj - Associate, AA Thornton
The majority of the world’s biggest selling medicines can be classified as “biologics” or “biopharmaceuticals”. Such medicines contain one or more biologically active product produced from (or containing components of)...
Is your IP Strategy fit for purpose? – Five Questions to Ask Yourself
As a result of the lockdown due to the global pandemic there is a greater need and renewed focus on using innovation to kick-start the economic recovery. The result is significant investment in R&D...
Is your Invention Plausible?
Alex Bone, Patent Attorney, Partner, AA Thornton
The market exclusivity provided by a patent can be crucial for allowing a company to obtain a return on their R&D investment.
A patent is essentially a deal in which,...
Shanks v Unilever – An opening of the claim floodgates?
Varuni Paranavitane, IP Solicitor, AA Thornton
At the end of last year Professor Shanks was awarded £2 million for an invention relating to a glucose sensor made while employed working for Unilever. What does this mean...
UK offers accelerated patent protection for eco-friendly innovations
Using the Green Channel to accelerate a UK patent application.
AdamsonJones was able to obtain patent protection for client, LLEO Ltd, in just 15 months from the moment the Green Channel was used. This acceleration was crucial as...
Know your third party patent rights
In the competitive world of the biosciences, third party patent rights (TPRs) can stand in the way of a planned course of action, even after significant investment has been made. Knowledge of such rights...
The IP journey and risk mitigation
Paul Storer
Senior Policy Adviser in the Business Support Policy Team at the IPO
Resolving IP disputes can be costly and the Intellectual Property Office continues to seek to reduce costs for businesses, not only in...